Home Newsfeeds Exane BNP Paribas Initiates Coverage On Omnicom Group with Underperform Rating

Exane BNP Paribas Initiates Coverage On Omnicom Group with Underperform Rating

Exane BNP Paribas analyst Lina Ghayor initiates coverage on Omnicom Group (NYSE:OMC) with a Underperform rating.

byBenzinga Newsdesk

August 25, 2022

1 minute read

Exane BNP Paribas analyst Lina Ghayor initiates coverage on Omnicom Group (NYSE:OMC) with a Underperform rating.

Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More

By Lara Goldstein

January 25, 1:02 PM

Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First?

CLABF

Verona Pharma To Announce Top-line Data From Phase 3 ENHANCE-1 Trial Of Nebulized Ensifentrine For COPD On Tuesday, December 20, 2022

By Benzinga Newsdesk

December 19, 5:02 PM

Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it will report top-line Phase 3 data from its

VRNA

What’s Going On With AMC Entertainment Stock?

By Adam Eckert

September 19, 12:01 PM

AMC Entertainment Holdings Inc (NYSE: AMC) shares are moving lower Tuesday, adding to significant losses over the last month.

AMC

Global
News

Microbot Medical Shares Status Following Recent Geopolitical Events; Says All Regulatory, Clinical, Operational And Pre-Commercial Activities Continue To Stay On Track Despite The On-Going Situation In Israel

By Benzinga Newsdesk

April 15, 8:31 AM

All Regulatory, Clinical, Operational and Pre-Commercial Activities Continue to Stay on Track Despite the On-going Situation in Israel Company Believes that Both Regulatory and Commercial Milestones to be Achieved

MBOT

Exane BNP Paribas Initiates Coverage On Omnicom Group with Underperform Rating

Related Posts

Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More

Verona Pharma To Announce Top-line Data From Phase 3 ENHANCE-1 Trial Of Nebulized Ensifentrine For COPD On Tuesday, December 20, 2022

What’s Going On With AMC Entertainment Stock?

Microbot Medical Shares Status Following Recent Geopolitical Events; Says All Regulatory, Clinical, Operational And Pre-Commercial Activities Continue To Stay On Track Despite The On-Going Situation In Israel